GlassScriptPhysician profile
Jill Ann Ferretti
NPI 1093490161
$5,369.27
in general payments reported to CMS, 2019-2025
30 companies · $3,122 in 2025
The $3,122 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,247 · 2025: $3,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,369.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $842.19 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $493.07 | 2024-2025 | Xifaxan, Relistor |
| Aimmune Therapeutics, INC. | $486.57 | 2024-2025 | Zenpep, Vowst |
| Phathom Pharmaceuticals, INC. | $465.45 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $455.94 | 2025 | Rezdiffra |
| Ardelyx, INC. | $395.95 | 2024-2025 | Ibsrela |
| Janssen Biotech, INC. | $372.03 | 2024-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $335.07 | 2024-2025 | Dupixent |
| Pfizer INC. | $282.74 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $252.50 | 2024-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $183.99 | 2024-2025 | Omvoh, Mounjaro |
| Novo Nordisk INC | $140.11 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $88.33 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $74.47 | 2024 | Farxiga, Airsupra, Breztri |
| Janssen Scientific Affairs, LLC | $70.19 | 2024 | Tremfya |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $63.22 | 2024 | Rexulti |
| Gilead Sciences, INC. | $57.52 | 2024-2025 | |
| Glaxosmithkline, LLC. | $43.55 | 2024 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $38.71 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.51 | 2024 | Jardiance, Tradjenta, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $25.88 | 2024 | Spravato, Xarelto |
| Orphalan INC | $25.85 | 2025 | Cuvrior |
| Genzyme Corporation | $24.33 | 2024 | |
| Ferring Pharmaceuticals INC. | $22.84 | 2024 | Rebyota |
| Celgene Corporation | $22.14 | 2024 | Zeposia |
| Shield Therapeutics INC | $16.23 | 2024 | |
| Sanofi Pasteur INC. | $15.71 | 2025 | |
| Amgen INC. | $15.18 | 2024 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $14.96 | 2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $14.04 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Ferretti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.